In recent years, robots have been used not only in
industry, but also in medical systems. Current research
on the use of robots in the medical community is focused on surgical robots,
rehabilitation robots, nursing robots and service robots.
A surgical robot is a combined device of a group of
instruments. It is usually assembled from a device such as an endoscope,
surgical instruments such as scissors, a miniature camera and a joystick. According to foreign manufacturers, the surgical robots currently in use
work on the principle of surgical operations carried out wirelessly, i.e. the
doctor sits in front of a computer monitor and carefully observes the lesion in
the patient\'s body through the monitor and endoscope, and then removes the
lesion precisely by means of a scalpel in the robot\'s hands.Surgical robots are
among the most widely used and promising, offering powerful capabilities to
overcome the poor precision, long operating times, surgeon fatigue and lack of
3D precision vision found in traditional surgical procedures. Its market is segmented into several major sections, such as gynaecology,
urology, general surgery, orthopaedics. etc. Gynecology holds a significant
share in terms of application and is expected to reach 34.05% of revenue by
2030, growing at a CAGR of 18.87% during 2020 and 2030.
Get
the complete sample, please click:https://www.globalmarketmonitor.com/reports/762636-robotic-surgical-procedures-market-report.html
Surgical Robotics Market
Analysis
The global medical robotics market is expected to
reach US$ 18,000 million by 2020. Of this, the market for surgical robots is
expected to reach USD 6,000 million, with the consumables segment contributing
more than 50%.
Surgical robots are growing at an average rate of
14% globally and over 23% in Asia Pacific. Such a growth rate is extremely rare
in the medical device sector and has therefore received a high level of
attention from the technology, medical and investment sectors.
The surgical operation robot, represented by the da
Vinci robot, started in the field of urology and its disease areas have rapidly
expanded to include general surgery, gynaecology, hepatobiliary surgery,
vascular surgery, paediatric surgery, thoracic surgery, cardiac surgery and
many other departments.
Global revenue in 2019 is US$4400 Mn, of which
consumables revenue contributes US$2400 Mn and net profit is over 30%. Other
international giants in the medical field are also heavily involved in the
field of surgical robotics. Surgical robots are becoming an important direction
in the development of surgery.
Analysis of the Domestic Competitive
Landscape for Surgical Robots
The domestic operating class surgical robot market
started late, and there are no enterprises with scale yet, most companies are
still in the stage of research and development, animal experiments, clinical
experiments, research direction to single-hole, laparoscopic surgery system
with flexible robotic arm is the main. Positioning class
surgical robots, represented by Tianzhihang, Huazhi minimally invasive,
Parkwise Wellcome and Huake Precision, have been industrialised or are about to
be industrialised.
So far, nine domestic surgical robots have been
marketed, including two orthopaedic surgical robots by Tianzhihang, five
neurosurgical robots by Baihuiwei Kang, Huake Precision and Huazhi Minimally
Invasive, and the first domestic oral surgery robot "Ruimab" by
Baihuiwei Kang.
From the layout of the industry chain, in the field
of operating robots, Jingfeng Medical\'s single-hole laparoscopic surgical robot
may adopt a design close to that of the da Vinci surgical robot, and is the
only company in China and the second company in the world that has mastered
both single-hole surgical robot and multi-hole surgical robot technology. It
has formed a complete intellectual property system and applied for more than
300 patents at home and abroad.
In the field of positioning class robots,
Tianzhihang has carried out horizontal expansion in different medical device
fields in the midstream segment: in 2017, Tianzhihang invested in French
company SPW to lay out the field of orthopaedic spine class high-value
consumables; in 2018, Tianzhihang invested in US company GYS and US company
Mobius to start to involve in the field of mobile CT in the field of imaging
equipment, which is expected to reduce the industry chain penetration of
horizontal midstream products through The company is expected to reduce product
costs through the integration of horizontal midstream products. Huake Precision has a good channel base to boost the marketing of its
surgical robot products: the company\'s electrode products already occupy 90% of
the market share in the field of neurosurgery in China, and its extensive sales
channels are expected to boost the development of its surgical robots. As one of the first stereotactic robots, Huazhi\'s CAS-R series has now
nationalised its components and the procedures it covers have been reimbursed
by Beijing Medical Insurance.
In terms of market space, the surgical handling
robot is oriented to a wide range of clinical areas, with a large volume of
surgery and a large potential future market. With big water and big fish, it is easy to gather resources in many
aspects, such as technology, talent and capital. From the industry stage, da
Vinci has gone through a long period of market education, allowing the surgical
operation robot industry to pass the cognitive period and begin to enter the
development period, while its related patents gradually expire and
opportunities begin to emerge for domestic manufacturers. With Tianjin University and HUST as the source of technology, a number of
companies with relatively mature products have emerged. From the policy
environment, due to the number of configuration certificates, which limit the
amount of da Vinci installed, there will be inclined support in the future for
domestic products.
Domestic surgical robots with capability and
technology have the opportunity to grow faster. At the same time, the
recognition of Tianzhihang by the Science and Technology Board is a testament
to the positive attitude of the capital market in embracing hardcore
technology. In terms of segmentation, there must be a differentiation advantage.
Despite the banner of localisation, to impress the mainstream PI, one needs to
find differentiating features, procedures, product design, consumables design,
indication areas, etc. This will make it easy to get clinical and capital
market recognition. Among the domestic surgical robots, there are very good
companies in the direction of multi-hole, single-hole and flexible robots,
which deserve attention.
Get
the complete sample, please click:https://www.globalmarketmonitor.com/reports/762636-robotic-surgical-procedures-market-report.html
We provide more professional and intelligent market reports to complement your business decisions.
Chinese
